immatics wins 2012 TiE50 Award

30-05-2012: immatics biotechnologies GmbH announced that it has been named a 2012 TiE50 winner. These awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors.

immatics was chosen from more than 2,100 technology start-ups, judged by a panel of industry experts ranging from venture capital to entrepreneurs. The awards were showcased on 18-19 May 2012 at 2012 TiEcon in Santa Clara, California.

Paul Higham, immatics’ CEO, said: “The TiE50 Award acknowledges immatics’ significant progress in developing innovative therapies for difficult to treat cancers. The positive phase 2 results that we have reported with IMA901 for renal cell carcinoma and IMA910 for colorectal cancer highlight the potential for our multi-peptide cancer vaccines to play an important role in improving the treatment of cancer. The judges were impressed with the rapid development of our vaccines, particularly the fast transition of IMA901 into the phase 3 study. We expect to continue this good progress and to create products with meaningful benefits for patients.”

Contact / Request information

Request further information free of charge:

Request information now

Watchlist

This is where you can add this news to your personal favourites

On my watchlist

Request information now On my watchlist

Facts, background information, dossiers

More about Immatics Biotechnologies

News

immatics appoints Peter Chambré as Chairman

immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He wi ... more

Kidney Cancer Vaccine Successful in Clinical Trials

Researchers at the University of Tübingen and immatics biotechnologies GmbH – a start-up by Tübingen scientists – have published the results of two clinical studies using the kidney-cancer vaccine IMA901 in the latest edition of Nature Medicine. IMA901 is used to treat patients with cancer ... more

immatics wins 2012 TiE50 Award

immatics biotechnologies GmbH announced that it has been named a 2012 TiE50 winner. These awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors. immatics was chosen from more than 2,100 technology sta ... more

More news by Immatics Biotechnologies
Companies

Immatics Biotechnologies GmbH

immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body. Our goal is to support patients and physicians with new options in the fight against various cancers. Our means are synthetic peptides that specifically activate specialized white blo ... more